Scholarlink

<p>Traumatic brain injury (TBI) leads to extensive structural damage, neuronal loss, and functional deficits, along with marked disruption of cholinergic signaling and acute surges in acetylcholine. Biperiden, a muscarinic cholinergic antagonist, has emerged as a potential neuroprotective agent due to its ability to modulate synaptic plasticity and reduce excitotoxicity. Here, we evaluated the acute effects of biperiden in a translational non-human primate model of moderate TBI. Marmosets (<i>Callithrix jacchus,n</i> = 39) subjected to lateral fluid percussion injury (LFPI) received intraperitoneal biperiden (8&#xa0;mg/kg) beginning 6&#xa0;h post-injury, followed by two additional doses administered at 8&#xa0;h intervals. At 24&#xa0;h post-injury, brain tissue and serum were assessed using histology, immunofluorescence, and Single Molecule Array (SIMOA). Twenty-four hours post-trauma, biperiden treatment reduced hippocampal neuronal degeneration, decreased UCH-L1 levels, and attenuated astrocyte activation compared to saline-treated controls. Although biperiden is a clinically characterized muscarinic antagonist, the direct muscarinic target was not assessed in this primate model. These findings provide preliminary evidence that repeated dosing with biperiden may modulate early neurovascular and glial responses and provide acute neuroprotection following moderate TBI in marmosets, mitigating neuronal injury, excitotoxicity, and inflammation. This work highlights biperiden as a promising therapeutic candidate for early intervention after TBI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neurovascular and inflammatory effects of biperiden in the acute phase of moderate traumatic brain injury: evidence from a non-human primate model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Viviam Sanabria,
  • Christiane Gimenes,
  • Simone Romariz,
  • Amarildo Souza Gois,
  • Matheus B. Braga,
  • Michele Longoni Calió,
  • Juliana Lima Willers,
  • Maira L. Foresti,
  • Luiz Eugênio Mello,
  • Beatriz M. Longo

摘要

Traumatic brain injury (TBI) leads to extensive structural damage, neuronal loss, and functional deficits, along with marked disruption of cholinergic signaling and acute surges in acetylcholine. Biperiden, a muscarinic cholinergic antagonist, has emerged as a potential neuroprotective agent due to its ability to modulate synaptic plasticity and reduce excitotoxicity. Here, we evaluated the acute effects of biperiden in a translational non-human primate model of moderate TBI. Marmosets (Callithrix jacchus,n = 39) subjected to lateral fluid percussion injury (LFPI) received intraperitoneal biperiden (8 mg/kg) beginning 6 h post-injury, followed by two additional doses administered at 8 h intervals. At 24 h post-injury, brain tissue and serum were assessed using histology, immunofluorescence, and Single Molecule Array (SIMOA). Twenty-four hours post-trauma, biperiden treatment reduced hippocampal neuronal degeneration, decreased UCH-L1 levels, and attenuated astrocyte activation compared to saline-treated controls. Although biperiden is a clinically characterized muscarinic antagonist, the direct muscarinic target was not assessed in this primate model. These findings provide preliminary evidence that repeated dosing with biperiden may modulate early neurovascular and glial responses and provide acute neuroprotection following moderate TBI in marmosets, mitigating neuronal injury, excitotoxicity, and inflammation. This work highlights biperiden as a promising therapeutic candidate for early intervention after TBI.